Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 17.83 Million GBP | -6.03% |
| 2023 | 18.48 Million GBP | 135.01% |
| 2022 | 7.86 Million GBP | -48.42% |
| 2021 | 15.24 Million GBP | 19200.0% |
| 2020 | 79 Thousand GBP | 0.0% |
| 2019 | - GBP | 0.0% |
| 2018 | - GBP | 0.0% |
| 2017 | - GBP | 0.0% |
| 2016 | - GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | 0.0% |
| 2011 | - GBP | 0.0% |
| 2010 | - GBP | 0.0% |
| 2009 | - GBP | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 18.94 Million GBP | -2.88% |
| 2024 Q4 | 17.83 Million GBP | 0.0% |
| 2024 Q1 | 19.5 Million GBP | 5.56% |
| 2023 Q4 | 18.48 Million GBP | -3.88% |
| 2023 FY | 18.48 Million GBP | 135.01% |
| 2023 Q3 | 19.22 Million GBP | 110.06% |
| 2023 Q1 | 9.15 Million GBP | 16.39% |
| 2023 Q2 | 9.15 Million GBP | 0.0% |
| 2022 Q3 | 18.71 Million GBP | 148.98% |
| 2022 FY | 7.86 Million GBP | -48.42% |
| 2022 Q2 | 7.51 Million GBP | 0.0% |
| 2022 Q1 | 7.51 Million GBP | -50.71% |
| 2022 Q4 | 7.86 Million GBP | -57.98% |
| 2021 Q4 | 15.24 Million GBP | 0.0% |
| 2021 FY | 15.24 Million GBP | 19200.0% |
| 2021 Q3 | 15.24 Million GBP | 22322.06% |
| 2021 Q2 | 68 Thousand GBP | 0.0% |
| 2021 Q1 | 68 Thousand GBP | -13.92% |
| 2020 Q4 | 79 Thousand GBP | 0.0% |
| 2020 Q1 | - GBP | 0.0% |
| 2020 FY | 79 Thousand GBP | 0.0% |
| 2020 Q2 | - GBP | 0.0% |
| 2020 Q3 | 79 Thousand GBP | 0.0% |
| 2019 Q3 | - GBP | 0.0% |
| 2019 Q4 | - GBP | 0.0% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 Q2 | - GBP | 0.0% |
| 2019 FY | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2018 FY | - GBP | 0.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2018 Q3 | - GBP | 0.0% |
| 2017 Q1 | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2017 FY | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 FY | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2014 Q3 | - GBP | 0.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2014 Q1 | - GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 Q3 | - GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | - GBP | 0.0% |
| 2012 Q4 | - GBP | 0.0% |
| 2011 Q4 | - GBP | 0.0% |
| 2011 FY | - GBP | 0.0% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | - GBP | 0.0% |
| 2009 FY | - GBP | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 14.716% |
| Evofem Biosciences, Inc. | 8000.00 USD | -222800.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -915.791% |
| Mesoblast Limited | 100.29 Million USD | 82.22% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -30308.24% |
| Genus plc | 228.2 Million USD | 92.186% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -2572.946% |
| ContraFect Corporation | 2.21 Million USD | -706.878% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -1171.051% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -228.611% |
| MultiCell Technologies, Inc. | 36.43 USD | -48948568.68% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 67.935% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -701.078% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1351.691% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 89.265% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -839.284% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -10314.063% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -323412.337% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | 34.916% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -5437.888% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.841% |
| Halberd Corporation | 150 Thousand USD | -11788.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -5844.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -10759.596% |
| argenx SE | 15.35 Million USD | -16.139% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 12.21% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -400079.533% |
| Genscript Biotech Corporation | 287.12 Million USD | 93.79% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -14018.541% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -7677.017% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -3115.348% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -70384.999% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -115.779% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -6612.971% |
| ONE Bio Corp. | 592.19 Thousand USD | -2911.155% |
| Reve Technologies, Inc. | 1064.00 USD | -1675839.85% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -11818.671% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -11818.671% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -7663.474% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -12546.809% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -22190.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -128.032% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -4731.879% |
| International Stem Cell Corporation | 445 Thousand USD | -3907.191% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -118.798% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -3801.969% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -1435.917% |
| PureTech Health plc | 18.25 Million USD | 2.29% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -11788.0% |
| IXICO plc | 275 Thousand USD | -6384.364% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -50.621% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 32.221% |
| CSL Limited | 11.23 Billion USD | 99.841% |
| Cellectis S.A. | 36.21 Million USD | 50.755% |